Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Germany To Honor Pledge To Cut Spending On Medicines

Executive Summary

Germany looks set to introduce new measures to curb pharmaceutical spending, including higher mandatory rebates for outpatient drugs and combination products. It will also lower the threshold at which orphan drugs must undergo a benefit assessment.

You may also be interested in...



Re-Thinking Rare Disease

Germany is drastically squeezing orphan drug pricing while new US laws protect rare diseases drugs from price negotiations. These contrasting moves fuel the longstanding debate over whether orphans still deserve special incentives.

Germany: Leaked Pricing Measures Could Have ‘Drastic’ Consequences For Orphans

'Dangerous’ new measures outlined in a leaked bill would be a disaster for orphan drugs and lead to companies opting out of the German market, says one industry executive.

Orchard Secures New Libmeldy Price In Germany

Orchard Therapeutics says it is confident in the success of its gene therapy for MLD, which has secured the highest possible benefit rating from the German authorities.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS145869

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel